Toleranzia AB (TOL.ST)
SEK 0.61
(0.33%)
SEK 0.61
(0.33%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -7.45 Million SEK | 11.79% |
| 2022 | -8.45 Million SEK | -34.57% |
| 2021 | -6.28 Million SEK | -28.38% |
| 2020 | -4.89 Million SEK | 50.7% |
| 2019 | -9.92 Million SEK | -75.49% |
| 2018 | -5.65 Million SEK | -4.93% |
| 2017 | -5.39 Million SEK | -6.65% |
| 2016 | -5.05 Million SEK | -23.02% |
| 2015 | -4.1 Million SEK | -457.46% |
| 2014 | -737.22 Thousand SEK | -1992.3% |
| 2013 | 38.95 Thousand SEK | -3.08% |
| 2012 | 40.19 Thousand SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -2.8 Million SEK | -73.61% |
| 2024 Q2 | -1.61 Million SEK | -105.85% |
| 2024 Q1 | -786 Thousand SEK | 58.83% |
| 2023 Q2 | -2.5 Million SEK | -28.56% |
| 2023 Q4 | -1.9 Million SEK | -73.7% |
| 2023 Q1 | -1.94 Million SEK | 4.84% |
| 2023 FY | -7.45 Million SEK | 11.79% |
| 2023 Q3 | -1.09 Million SEK | 56.09% |
| 2022 Q2 | -2.21 Million SEK | -7.04% |
| 2022 Q3 | -2.12 Million SEK | 4.37% |
| 2022 Q4 | -2.04 Million SEK | 3.54% |
| 2022 FY | -8.45 Million SEK | -34.57% |
| 2022 Q1 | -2.07 Million SEK | -20.02% |
| 2021 Q4 | -1.72 Million SEK | -13.3% |
| 2021 Q2 | -1.57 Million SEK | -10.83% |
| 2021 FY | -6.28 Million SEK | -28.38% |
| 2021 Q1 | -1.42 Million SEK | 12.58% |
| 2021 Q3 | -1.52 Million SEK | 3.37% |
| 2020 FY | -4.89 Million SEK | 50.7% |
| 2020 Q2 | -891.72 Thousand SEK | 32.06% |
| 2020 Q4 | -1.62 Million SEK | -53.11% |
| 2020 Q3 | -1.06 Million SEK | -19.19% |
| 2020 Q1 | -1.31 Million SEK | 59.72% |
| 2019 Q3 | -1.84 Million SEK | -36.56% |
| 2019 FY | -9.92 Million SEK | -75.49% |
| 2019 Q2 | -1.34 Million SEK | -18.71% |
| 2019 Q1 | -1.13 Million SEK | 25.47% |
| 2019 Q4 | -3.25 Million SEK | -77.01% |
| 2018 Q4 | -1.52 Million SEK | -29.4% |
| 2018 FY | -5.65 Million SEK | -4.93% |
| 2018 Q3 | -1.17 Million SEK | 22.73% |
| 2018 Q2 | -1.52 Million SEK | -6.35% |
| 2018 Q1 | -1.43 Million SEK | 8.97% |
| 2017 Q2 | -1.59 Million SEK | -20.38% |
| 2017 FY | -5.39 Million SEK | -6.65% |
| 2017 Q3 | -899.24 Thousand SEK | 43.6% |
| 2017 Q1 | -1.32 Million SEK | 27.56% |
| 2017 Q4 | -1.57 Million SEK | -75.04% |
| 2016 Q1 | -1.1 Million SEK | 58.76% |
| 2016 FY | -5.05 Million SEK | -23.02% |
| 2016 Q4 | -1.82 Million SEK | -82.32% |
| 2016 Q3 | -1 Million SEK | 10.67% |
| 2016 Q2 | -1.12 Million SEK | -1.88% |
| 2015 Q2 | -533.36 Thousand SEK | -86.36% |
| 2015 Q1 | -286.19 Thousand SEK | -10.07% |
| 2015 Q3 | -618.03 Thousand SEK | -15.87% |
| 2015 FY | -4.1 Million SEK | -457.46% |
| 2015 Q4 | -2.67 Million SEK | -332.35% |
| 2014 FY | -737.22 Thousand SEK | -1992.3% |
| 2014 Q4 | -260.01 Thousand SEK | 0.0% |
| 2013 FY | 38.95 Thousand SEK | -3.08% |
| 2012 FY | 40.19 Thousand SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcuCort AB | -13.69 Million SEK | 45.519% |
| AlzeCure Pharma AB (publ) | -37.16 Million SEK | 79.931% |
| BioGaia AB (publ) | 365.35 Million SEK | 102.042% |
| Enzymatica AB (publ) | -49.72 Million SEK | 85.0% |
| Enorama Pharma AB (publ) | -44.61 Million SEK | 83.281% |
| Gabather AB (publ) | -9.43 Million SEK | 20.96% |
| Klaria Pharma Holding AB (publ.) | -35.78 Million SEK | 79.155% |
| Moberg Pharma AB (publ) | -21.09 Million SEK | 64.638% |
| Nanexa AB (publ) | -76.39 Million SEK | 90.237% |
| Newbury Pharmaceuticals AB (publ) | -15.4 Million SEK | 51.581% |
| ODI Pharma AB | 355.97 Thousand SEK | 2195.395% |
| Orexo AB (publ) | -128.3 Million SEK | 94.186% |
| Probi AB (publ) | 16.81 Million SEK | 144.349% |
| Swedencare AB (publ) | 58.6 Million SEK | 112.729% |
| Swedish Orphan Biovitrum AB (publ) | 2.4 Billion SEK | 100.31% |
| Vivesto AB | -367.03 Million SEK | 97.968% |